{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:37:34Z","timestamp":1789605454729,"version":"build-2803163510"},"reference-count":81,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec id=\"ab-yrv260005-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Lithium, a long-established cornerstone therapy for bipolar disorder, is a biologically plausible disease-modifying agent for neurodegenerative disorders, including mild cognitive impairment (MCI) and Alzheimer disease (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yrv260005-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      Rather than targeting a single pathology like amyloid or tau, lithium acts across multiple cellular resilience pathways. Chronic lithium exposure induces the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), enhances brain-derived neurotrophic factor (BDNF) signaling, inhibits glycogen synthase kinase-3\u03b2 (GSK-3\u03b2), stabilizes mitochondrial function, and reduces oxidative stress. These convergent mechanisms promote neuronal survival and synaptic integrity. In humans, proton magnetic resonance spectroscopy studies found that lithium increased\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      -acetylaspartate levels, consistent with improved neuronal viability, and structural magnetic resonance imaging (MRI) studies found that lithium preserved gray matter and\/or reversed illness-related atrophy in hippocampal and corticolimbic regions. In addition, extensive evidence demonstrates that low-dose lithium (approximately 0.3mM)\u2014significantly lower than traditional psychiatric doses (0.6-1.0mM)\u2014exerts robust neurotrophic and neuroprotective effects. Preclinical models have found that these concentrations stimulate hippocampal neurogenesis, promote structural plasticity, and protect against proteotoxic injury. Furthermore, epidemiological studies have associated cumulative lithium exposure with reduced dementia risk, and early randomized clinical trials in MCI suggest cognitive stabilization and favorable tau biomarker changes at low, well-tolerated doses. The recent repletion hypothesis suggests that lithium may also function as a physiological trace element, but these findings await independent replication.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yrv260005-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>These convergent data support a prospective clinical trial of low-dose lithium orotate to slow disease progression in MCI. Such an approach would prioritize established neuroprotective mechanisms while potentially mitigating the kidney and thyroid risks associated with higher-dose carbonate formulations. If low-dose lithium can indeed meaningfully alter disease trajectory, it would represent a much-needed, accessible, and inexpensive treatment that may be especially relevant in low- and middle-income countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2026.1296","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:30:56Z","timestamp":1781105456000},"page":"976","source":"Crossref","is-referenced-by-count":1,"title":["The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia"],"prefix":"10.1001","volume":"83","author":[{"given":"Gregory J.","family":"Moore","sequence":"first","affiliation":[{"name":"Departments of Radiology, Psychiatry, Neurology, and Neurosurgery, Penn State University College of Medicine, Hershey, Pennsylvania"},{"name":"Alzheimer\u2019s Disease Data Initiative, Kirkland, Washington"},{"name":"Gates Ventures, Kirkland, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Bose","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Data Initiative, Kirkland, Washington"},{"name":"Gates Ventures, Kirkland, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioline D.","family":"Henter","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husseini K.","family":"Manji","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Oxford University, Oxford, United Kingdom"},{"name":"Department of Psychiatry, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"Suppl 2","key":"yrv260005r2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1399-5618.2009.00714.x","article-title":"The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.","volume":"11","author":"Machado-Vieira","year":"2009","journal-title":"Bipolar Disord"},{"issue":"10","key":"yrv260005r3","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s40263-016-0380-1","article-title":"Therapeutic mechanisms of lithium in bipolar disorder: recent advances and current understanding.","volume":"30","author":"Malhi","year":"2016","journal-title":"CNS Drugs"},{"issue":"7","key":"yrv260005r4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0006-3223(99)00165-1","article-title":"Lithium at 50: have the neuroprotective effects of this unique cation been overlooked?","volume":"46","author":"Manji","year":"1999","journal-title":"Biol Psychiatry"},{"issue":"2","key":"yrv260005r5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1046\/j.1471-4159.1999.720879.x","article-title":"The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS.","volume":"72","author":"Chen","year":"1999","journal-title":"J Neurochem"},{"issue":"7","key":"yrv260005r6","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0028-3908(02)00217-4","article-title":"Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity.","volume":"43","author":"Hashimoto","year":"2002","journal-title":"Neuropharmacology"},{"issue":"16","key":"yrv260005r7","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.1073\/pnas.93.16.8455","article-title":"A molecular mechanism for the effect of lithium on development.","volume":"93","author":"Klein","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"yrv260005r8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fnmol.2011.00015","article-title":"GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke.","volume":"4","author":"Chuang","year":"2011","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"yrv260005r9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40345-025-00386-7","article-title":"Lithium and neuroprotection: a review of molecular targets and biological effects at subtherapeutic concentrations in preclinical models of Alzheimer\u2019s disease.","volume":"13","author":"De-Paula","year":"2025","journal-title":"Int J Bipolar Disord"},{"issue":"6","key":"yrv260005r10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1021\/cn5000309","article-title":"Neuroprotective effects of lithium: implications for the treatment of Alzheimer\u2019s disease and related neurodegenerative disorders.","volume":"5","author":"Forlenza","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"yrv260005r11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnmol.2012.00014","article-title":"Inhibition of GSK3 by lithium, from single molecules to signaling networks.","volume":"5","author":"Freland","year":"2012","journal-title":"Front Mol Neurosci"},{"issue":"8","key":"yrv260005r12","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/npp.2010.41","article-title":"Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study.","volume":"35","author":"Lyoo","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"9237","key":"yrv260005r13","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0140-6736(00)02793-8","article-title":"Lithium-induced increase in human brain grey matter.","volume":"356","author":"Moore","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"yrv260005r14","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.neubiorev.2010.10.001","article-title":"Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors.","volume":"35","author":"Berk","year":"2011","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"yrv260005r15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/acps.12305","article-title":"Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report.","volume":"130","author":"Kapczinski","year":"2014","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"yrv260005r16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1399-5618.2012.01013.x","article-title":"Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment.","volume":"14","author":"Hajek","year":"2012","journal-title":"Bipolar Disord"},{"issue":"5","key":"yrv260005r17","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1038\/s41380-025-03432-z","article-title":"Psychotropic medications and their interactions with subcortical brain volume in bipolar disorder: an ENIGMA mega-analysis.","volume":"31","author":"King","year":"2026","journal-title":"Mol Psychiatry"},{"issue":"4","key":"yrv260005r18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2174\/1570159X13666150403231654","article-title":"Brain structural effects of psychopharmacological treatment in bipolar disorder.","volume":"13","author":"McDonald","year":"2015","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"yrv260005r19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/ph18040467","article-title":"The mechanisms of lithium action: the old and new findings.","volume":"18","author":"Sakrajda","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"yrv260005r20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1503\/jpn.180002","article-title":"Brain grey-matter volume alteration in adult patients with bipolar disorder under different conditions: a voxel-based meta-analysis.","volume":"44","author":"Wang","year":"2019","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"yrv260005r21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.47626\/1516-4446-2022-2767","article-title":"Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment.","volume":"45","author":"Damiano","year":"2023","journal-title":"Braz J Psychiatry"},{"key":"yrv260005r22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.brainres.2007.09.054","article-title":"Lithium reduces ischemia-induced hippocampal CA1 damage and behavioral deficits in gerbils.","volume":"1184","author":"Bian","year":"2007","journal-title":"Brain Res"},{"issue":"10","key":"yrv260005r23","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1074\/jbc.274.10.6039","article-title":"Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. a prominent role in neuroprotection against excitotoxicity.","volume":"274","author":"Chen","year":"1999","journal-title":"J Biol Chem"},{"issue":"2","key":"yrv260005r24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/sj.tpj.6500296","article-title":"Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2.","volume":"5","author":"Hiroi","year":"2005","journal-title":"Pharmacogenomics J"},{"issue":"11","key":"yrv260005r25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113607","article-title":"The mood-stabilizer lithium prevents hippocampal apoptosis and improves spatial memory in experimental meningitis.","volume":"9","author":"Liechti","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"yrv260005r26","doi-asserted-by":"publisher","first-page":"7428","DOI":"10.1038\/s41598-020-64202-1","article-title":"Lithium response in bipolar disorder correlates with improved cell viability of patient derived cell lines.","volume":"10","author":"Paul","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"yrv260005r27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/sj.mp.4001463","article-title":"Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington\u2019s disease.","volume":"9","author":"Senatorov","year":"2004","journal-title":"Mol Psychiatry"},{"key":"yrv260005r28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fnins.2014.00457","article-title":"Lithium-induced neuroprotection is associated with epigenetic modification of specific BDNF gene promoter and altered expression of apoptotic-regulatory proteins.","volume":"8","author":"Dwivedi","year":"2015","journal-title":"Front Neurosci"},{"issue":"2","key":"yrv260005r29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1742-7843.2009.00416.x","article-title":"Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL\/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus.","volume":"105","author":"Hammonds","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"yrv260005r30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s002130100871","article-title":"Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain.","volume":"158","author":"Fukumoto","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"yrv260005r31","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0960-9822(02)70790-2","article-title":"Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells.","volume":"6","author":"Stambolic","year":"1996","journal-title":"Curr Biol"},{"issue":"2","key":"yrv260005r32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.biopsych.2006.02.027","article-title":"Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder.","volume":"61","author":"Li","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"19","key":"yrv260005r33","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.","volume":"102","author":"Noble","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"yrv260005r34","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.1028963","article-title":"Inhibition of glycogen synthase kinase 3 by lithium, a mechanism in search of specificity.","volume":"15","author":"Chatterjee","year":"2022","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"yrv260005r35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrn3229","article-title":"Impaired mitochondrial function in psychiatric disorders.","volume":"13","author":"Manji","year":"2012","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"yrv260005r36","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1073\/pnas.95.5.2642","article-title":"Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx.","volume":"95","author":"Nonaka","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"yrv260005r37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1017\/S1461145708009802","article-title":"Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage.","volume":"12","author":"Bachmann","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"yrv260005r38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1017\/S1461145712000132","article-title":"Neuroprotective effects of chronic exposure of SH-SY5Y to low lithium concentration involve glycolysis stimulation, extracellular pyruvate accumulation and resistance to oxidative stress.","volume":"16","author":"Nciri","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"yrv260005r39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3389\/fnins.2015.00403","article-title":"Potential application of lithium in Parkinson\u2019s and other neurodegenerative diseases.","volume":"9","author":"Lazzara","year":"2015","journal-title":"Front Neurosci"},{"issue":"2","key":"yrv260005r40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pneurobio.2006.12.003","article-title":"N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology.","volume":"81","author":"Moffett","year":"2007","journal-title":"Prog Neurobiol"},{"issue":"3","key":"yrv260005r41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1503\/jpn.110097","article-title":"Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study.","volume":"37","author":"Hajek","year":"2012","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"yrv260005r42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0006-3223(00)00252-3","article-title":"Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?","volume":"48","author":"Moore","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"2","key":"yrv260005r43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00004850-200303000-00002","article-title":"Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients.","volume":"18","author":"Silverstone","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"issue":"6627","key":"yrv260005r44","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/386824a0","article-title":"Subgenual prefrontal cortex abnormalities in mood disorders.","volume":"386","author":"Drevets","year":"1997","journal-title":"Nature"},{"issue":"5","key":"yrv260005r45","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4088\/JCP.07m03745","article-title":"A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients.","volume":"70","author":"Moore","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"22","key":"yrv260005r46","doi-asserted-by":"publisher","first-page":"13290","DOI":"10.1073\/pnas.95.22.13290","article-title":"Glial reduction in the subgenual prefrontal cortex in mood disorders.","volume":"95","author":"Ong\u00fcr","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"yrv260005r47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.biopsych.2006.10.027","article-title":"Greater cortical gray matter density in lithium-treated patients with bipolar disorder.","volume":"62","author":"Bearden","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"2","key":"yrv260005r48","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-220813","article-title":"Low-dose lithium supplementation influences GSK3\u00df activity in a brain region specific manner in C57BL6 male mice.","volume":"91","author":"Fenech","year":"2023","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"yrv260005r49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014382","article-title":"Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice.","volume":"5","author":"Fiorentini","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"yrv260005r50","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0257-17.2017","article-title":"A novel neuroprotective mechanism for lithium that prevents association of the p75NTR-sortilin receptor complex and attenuates proNGF-induced neuronal death in vitro and in vivo.","volume":"5","author":"Greenwood","year":"2018","journal-title":"eNeuro"},{"issue":"4","key":"yrv260005r51","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1113\/EP088061","article-title":"Low-dose lithium feeding increases the SERCA2a-to-phospholamban ratio, improving SERCA function in murine left ventricles.","volume":"105","author":"Hamstra","year":"2020","journal-title":"Exp Physiol"},{"issue":"4","key":"yrv260005r52","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2174\/1570159X20666220302151224","article-title":"Beyond its psychiatric use: the benefits of low-dose lithium supplementation.","volume":"21","author":"Hamstra","year":"2023","journal-title":"Curr Neuropharmacol"},{"issue":"14","key":"yrv260005r53","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14517","article-title":"GSK3 inhibition with low dose lithium supplementation augments murine muscle fatigue resistance and specific force production.","volume":"8","author":"Whitley","year":"2020","journal-title":"Physiol Rep"},{"issue":"5","key":"yrv260005r54","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1399-5618.2009.00729.x","article-title":"Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue.","volume":"11","author":"Maurer","year":"2009","journal-title":"Bipolar Disord"},{"issue":"10","key":"yrv260005r55","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamapsychiatry.2017.2362","article-title":"Association of lithium in drinking water with the incidence of dementia.","volume":"74","author":"Kessing","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yrv260005r56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1192\/bjp.bp.114.154047","article-title":"Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study.","volume":"207","author":"Gerhard","year":"2015","journal-title":"Br J Psychiatry"},{"issue":"5","key":"yrv260005r57","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1192\/bjp.bp.110.080044","article-title":"Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial.","volume":"198","author":"Forlenza","year":"2011","journal-title":"Br J Psychiatry"},{"issue":"5","key":"yrv260005r58","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1192\/bjp.2019.76","article-title":"Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial.","volume":"215","author":"Forlenza","year":"2019","journal-title":"Br J Psychiatry"},{"issue":"4","key":"yrv260005r59","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/jamaneurol.2026.0072","article-title":"Low-dose lithium for mild cognitive impairment: a pilot randomized clinical trial.","volume":"83","author":"Gildengers","year":"2026","journal-title":"JAMA Neurol"},{"issue":"2","key":"yrv260005r60","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3233\/JAD-150437","article-title":"Lithium as a treatment for Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"48","author":"Matsunaga","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"yrv260005r61","first-page":"104","article-title":"Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer\u2019s disease.","volume":"10","author":"Nunes","year":"2013","journal-title":"Curr Alzheimer Res"},{"issue":"15","key":"yrv260005r62","doi-asserted-by":"publisher","first-page":"7756","DOI":"10.3390\/ijerph18157756","article-title":"The present state of lithium for the prevention of dementia related to Alzheimer\u2019s dementia in clinical and epidemiological studies: a critical review.","volume":"18","author":"Ishii","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"yrv260005r63","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/acps.13153","article-title":"Risk of dementia in bipolar disorder and the interplay of lithium: a systematic review and meta-analyses.","volume":"141","author":"Velosa","year":"2020","journal-title":"Acta Psychiatr Scand"},{"issue":"8081","key":"yrv260005r64","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-025-09335-x","article-title":"Lithium deficiency and the onset of Alzheimer\u2019s disease.","volume":"645","author":"Aron","year":"2025","journal-title":"Nature"},{"issue":"8081","key":"yrv260005r65","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/d41586-025-02255-w","article-title":"Does lithium deficiency contribute to Alzheimer\u2019s disease?","volume":"645","author":"Bush","year":"2025","journal-title":"Nature"},{"issue":"23","key":"yrv260005r67","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1089\/neu.2017.5509","article-title":"Lithium improves dopamine neurotransmission and increases dopaminergic protein abundance in the striatum after traumatic brain injury.","volume":"35","author":"Carlson","year":"2018","journal-title":"J Neurotrauma"},{"key":"yrv260005r68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jns.2019.05.016","article-title":"Targeting kinases in Parkinson\u2019s disease: a mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium.","volume":"402","author":"Guttuso","year":"2019","journal-title":"J Neurol Sci"},{"issue":"6","key":"yrv260005r69","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.3892\/mmr.2019.10152","article-title":"Neuroprotective effects of lithium on a chronic MPTP mouse model of Parkinson\u2019s disease via regulation of a-synuclein methylation.","volume":"19","author":"Zhao","year":"2019","journal-title":"Mol Med Rep"},{"issue":"10","key":"yrv260005r70","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/jnr.22700","article-title":"Lithium protects against oxidative stress-mediated cell death in a-synuclein-overexpressing in vitro and in vivo models of Parkinson\u2019s disease.","volume":"89","author":"Kim","year":"2011","journal-title":"J Neurosci Res"},{"issue":"6","key":"yrv260005r71","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/j.1471-4159.2006.04139.x","article-title":"Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.","volume":"99","author":"Engel","year":"2006","journal-title":"J Neurochem"},{"issue":"4","key":"yrv260005r72","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/JAD-2003-5405","article-title":"Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model.","volume":"5","author":"P\u00e9rez","year":"2003","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"yrv260005r73","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s42003-022-03051-2","article-title":"The neuroprotective mechanism of lithium after ischaemic stroke.","volume":"5","author":"Chen","year":"2022","journal-title":"Commun Biol"},{"issue":"3","key":"yrv260005r74","doi-asserted-by":"publisher","first-page":"519","DOI":"10.5603\/FM.a2022.0068","article-title":"Lithium chloride promotes neural functional recovery after local cerebral ischaemia injury in rats through Wnt signalling pathway activation.","volume":"82","author":"Junde","year":"2023","journal-title":"Folia Morphol (Warsz)"},{"key":"yrv260005r75","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.freeradbiomed.2023.07.004","article-title":"Lithium co-administration with rutin improves post-stroke neurological outcomes via suppressing Gsk-3\u00df activity in a rat model.","volume":"207","author":"Rana","year":"2023","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"yrv260005r76","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3109\/10799893.2015.1108338","article-title":"Delayed neuroprotection against cerebral ischemia reperfusion injury: putative role of BDNF and GSK-3\u00df.","volume":"36","author":"Taliyan","year":"2016","journal-title":"J Recept Signal Transduct Res"},{"issue":"5","key":"yrv260005r77","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3892\/etm.2020.9237","article-title":"Lithium chloride ameliorated spatial cognitive impairment through activating mTOR phosphorylation and inhibiting excessive autophagy in the repeated cerebral ischemia-reperfusion mouse model.","volume":"20","author":"Xiao","year":"2020","journal-title":"Exp Ther Med"},{"issue":"6","key":"yrv260005r78","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.2042-7158.1978.tb13258.x","article-title":"Rat brain and serum lithium concentrations after acute injections of lithium carbonate and orotate.","volume":"30","author":"Kling","year":"1978","journal-title":"J Pharm Pharmacol"},{"issue":"8","key":"yrv260005r80","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2262","article-title":"Lithium orotate: a superior option for lithium therapy?","volume":"11","author":"Pacholko","year":"2021","journal-title":"Brain Behav"},{"key":"yrv260005r81","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jpsychires.2023.06.012","article-title":"Different pharmacokinetics of lithium orotate inform why it is more potent, effective, and less toxic than lithium carbonate in a mouse model of mania.","volume":"164","author":"Pacholko","year":"2023","journal-title":"J Psychiatr Res"},{"key":"yrv260005r1","volume-title":"Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression","author":"Goodwin","year":"2007","edition":"2nd ed"},{"key":"yrv260005r66","unstructured":"Topol? E. Lithium and its potential protection from Alzheimer\u2019s disease. August 9, 2025. Accessed January 2026. https:\/\/erictopol.substack.com\/p\/lithium-and-its-potential-protection."},{"key":"yrv260005r79","unstructured":"Lowe? D. Lithium orotate revisited. August 5, 2025. Accessed February 2026. https:\/\/www.science.org\/content\/blog-post\/lithium-orotate-revisited"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2850078\/jamapsychiatry_moore_2026_rv_260005_1788289919.04352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:00:36Z","timestamp":1788361236000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2850078"}},"subtitle":["A Narrative Review"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.1296","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}